FDA’s Richard Pazdur to receive the 2025 AACR Enduring Impact Award for transformative service to cancer science and medicine

Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies

Vinay Prasad, a MAHA-aligned hematologist-oncologist with an avid cyber following, was named director of the FDA Center for Biologics Evaluation and Research, where he will be responsible for the agency’s regulation of vaccines and biologics, including cell and gene therapies.

May 09, 2025

Vol.51 No.18

By Claire Marie Porter

Cancer Policy

AACR calls on Congress to reject Trump’s FY2026 budget request for NIH

The American Association for Cancer Research called on Congress to stand up in unified opposition to President Trump’s FY2026 budget proposal for NIH, and to instead allocate a robust funding increase to $51.3 billion for the NIH (The Cancer Letter, May 2, 2025).

Scott Gottlieb, Mark McClellan warn of the major challenges created by planned reorganization of FDA

Scott GottliebMark B. McClellanTwo former FDA commissioners—Scott Gottlieb and , Mark B. McClellan—

First ODAC meeting since Trump’s inauguration scheduled for May 20-21

FDA announced a meeting of the Oncologic Drugs Advisory Committee May 20 and 21. It will be the first ODAC meeting since President Trump was inaugurated.

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.

May 09, 2025

Vol.51 No.18

Bertagnolli: NIH funding cuts are “unprecedented and harmful”
AACR panel challenges scientists to find stability in a period of “ventricular tachycardia”

“We stand at the edge of discovery, and on the brink of losing it,” said Patricia M. LoRusso, the 2024-2025 president of the American Association for Cancer Research. “I believe this is the most scientifically promising moment in the history of cancer research.”

May 02, 2025

Vol.51 No.17

By Claire Marie Porter

FDA’s Richard Pazdur to receive the 2025 AACR Enduring Impact Award for transformative service to cancer science and medicine

YOU MAY BE INTERESTED IN

Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies

AACR calls on Congress to reject Trump’s FY2026 budget request for NIH

Scott Gottlieb, Mark McClellan warn of the major challenges created by planned reorganization of FDA

First ODAC meeting since Trump’s inauguration scheduled for May 20-21

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

Bertagnolli: NIH funding cuts are “unprecedented and harmful”
AACR panel challenges scientists to find stability in a period of “ventricular tachycardia”

Renew today!

Subscriber content

Never miss an issue!

Login

FDA’s Richard Pazdur to receive the 2025 AACR Enduring Impact Award for transformative service to cancer science and medicine

YOU MAY BE INTERESTED IN

Cyber-iconoclast Vinay Prasad named head of FDA’s CBERAn oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies

AACR calls on Congress to reject Trump’s FY2026 budget request for NIH

Scott Gottlieb, Mark McClellan warn of the major challenges created by planned reorganization of FDA

First ODAC meeting since Trump’s inauguration scheduled for May 20-21

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC

Bertagnolli: NIH funding cuts are “unprecedented and harmful”AACR panel challenges scientists to find stability in a period of “ventricular tachycardia”

Never miss an issue!

Login

Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies

Bertagnolli: NIH funding cuts are “unprecedented and harmful”
AACR panel challenges scientists to find stability in a period of “ventricular tachycardia”